CAMP4 Therapeutics downgraded by Analyst
$CAMP
Analyst downgraded CAMP4 Therapeutics from Overweight to Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/14/2026 | $7.00 | Buy | Rodman & Renshaw |
| 10/2/2025 | $7.00 | Overweight | Cantor Fitzgerald |
| 9/16/2025 | Overweight → Neutral | Analyst | |
| 5/27/2025 | $8.00 | Outperform | Wedbush |
| 11/5/2024 | Outperform | William Blair | |
| 11/5/2024 | $18.00 | Overweight | Piper Sandler |
| 11/5/2024 | $23.00 | Overweight | JP Morgan |
| 8/16/2022 | $8.00 → $10.00 | Hold → Buy | Craig Hallum |
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on May 15, 2026 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase 5,000 shares of the Company's common stock to a newly hired employee of the Company as an inducement material to such employee's entry into employment with the Compan
CMP-002 administration resulted in a statistically significant improvement in seizure phenotypes and parameters in a SYNGAP1 haploinsufficient mouse model Results build upon prior preclinical evidence of neurodevelopmental benefit and suggest the potential for broader therapeutic impact CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the presentation of new precl
Submitted first clinical trial regulatory filing for CMP-002 in Australia, with additional global regulatory filings planned in 2026; anticipates initiation of global Phase 1/2 clinical trial in SYNGAP1 patients in 2H 2026 Received Orphan Designation for CMP-002 by the European Medicines Agency (EMA) Entered into collaboration with CURE SYNGAP1 to support ProMMiS, a natural history study to advance understanding of SYNGAP1 related disorder Cash runway expected into 2028, with $99 million in cash and cash equivalents as of 3/31/26 CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company develop
Rodman & Renshaw initiated coverage of CAMP4 Therapeutics with a rating of Buy and set a new price target of $7.00
Cantor Fitzgerald initiated coverage of CAMP4 Therapeutics with a rating of Overweight and set a new price target of $7.00
Analyst downgraded CAMP4 Therapeutics from Overweight to Neutral
SCHEDULE 13G - Camp4 Therapeutics Corp (0001736730) (Subject)
8-K - Camp4 Therapeutics Corp (0001736730) (Filer)
10-Q - Camp4 Therapeutics Corp (0001736730) (Filer)
IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company that helps organizations monitor, track and protect their vital assets, today reported financial results for its third quarter of fiscal year 2024 ended November 30, 2023. Third Quarter Fiscal Year 2024 Financial Overview Revenue was $53.6 million, representing a 13% decline QoQ and a 32% decline YoY driven primarily by softer demand in the TSP market segment.Gross margin was 33%, representing a decline of approximately 340 bps QoQ and 100 bps decline YoY as a result of a shift in product mix and a higher-than-normal reserve for excess and obsolete inventory.S&SS revenue was $34.5
IRVINE, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a leading telematics solution provider that helps organizations improve operational performance, today announced that it will release its fiscal 2024 third quarter financial results after market close on Tuesday, January 9, 2024. In addition, the Company will host a conference call at 5:00 p.m. Eastern (2:00 p.m. Pacific) on January 9, 2024, to discuss its financial results. The call may be accessed via webcast by visiting the Investor Relations section of CalAmp's website at CalAmp IR Web Site. Please go to the website at least 15 minutes early to register, download and install any necessary audio software. A repla
IRVINE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, today announced the closing of a $45 million strategic financing with Lynrock Lake Master Fund LP ("Lynrock") in the form of a term loan maturing in November 2027. Lynrock is an existing holder of a large majority of CalAmp's 2.00% Convertible Senior Notes maturing in August 2025 (the "Notes"). In connection with the execution of the term loan agreement, CalAmp is amending the Notes to add a security interest. "As a long-standing investor in CalAmp, we are pleased to provide the company with add
SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)
SC 13D - Camp4 Therapeutics Corp (0001736730) (Subject)
SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)
CAMBRIDGE, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the appointment of Michael MacLean to the Company's Board of Directors. "Mike brings an exceptional depth of financial and operational expertise built across decades of leadership at some of the most innovative biotechnology companies, and we are thrilled to welcome him to CAMP4's Board," said Josh Mandel-Brehm, Pr
Paris, France--(Newsfile Corp. - June 30, 2025) - Sequans Communications S.A. (NYSE:SQNS), a leading innovator in cellular IoT semiconductor solutions, today announced the appointment of Jason W. Cohenour to its Board of Directors.Mr. Cohenour brings more than 30 years of executive leadership experience across sales, operations, and international mergers and acquisitions. He served as President, CEO, and Director of Sierra Wireless, Inc. (TSX:SW) (NASDAQ:SWIR) from 2005 to 2018, where he led a strategic transformation that created a global leader in the Internet of Things and drove company revenues to nearly USD $800 million. Prior to his CEO role, he held several senior positions at Sierra
With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, will provide strategic guidance for CAMP4's multiple drug development efforts CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced the appointments of Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, to the Company's Board of Directors. "We are delighted to welcome Drs. William